CBD is just one of over 100 different cannabinoid compounds.
And that's only counting the ones that have already been discovered.
Each of these compounds, and all their possible combinations, represent a veritable ocean of new possibilities for medical researchers.
This week, it's all about "TBTF" banks – as in, "too big to fizzle."
There's a lot riding on the financials, but I'm looking at pharma and healthcare, too, and I'll tell you why in a minute.
Fact is, this is one of the most important earnings seasons in recent memory, and investors are flat-out worried that it'll be one of the worst earnings seasons in recent memory.
JPMorgan Chase & Co. officially kicked off Q1 earnings season on Friday with a welcome revenue beat that nudged stocks gently upward for the day.
On the other hand, Bank of America Corp. reported a bumper crop of profits on Monday, but the shares slumped anyway because CFO Paul Donofrio voiced concerns about the slowing pace of interest rates – a big driver of bank profits.
Same deal with Goldman Sachs: It had a convincing earnings beat and a tasty dividend hike, but a drop in trading revenue sent the shares lower.
That shares didn't necessarily take off is a pretty good indicator of the worry out there in the streets. Freaked-out investors are punishing stocks for "sins" they might've forgiven two or three quarters back.
Me? I'm not sure it'll be the worst earnings season in years, but it's certainly going to be the one of most eventful.
by Greg Miller
Just last week, I spent two days at the 2019 Cannabis Science Conference East here in my hometown of Baltimore, Md.
The operative word there is "science," and let me tell you, there is a lot of science driving the cannabis market forward that will lead to a ton of profit opportunities.
We're mapping genomes, studying plant fertilization, and learning how to prescribe cannabis to treat ailments as quickly and effectively as possible.
Over the course of two days, there were over 60 presentations covering topics ranging from equipment and methods to analyze cannabis plants, extracts, and cannabinoids; techniques to optimize cultivation; and the latest developments in medical cannabis research.
The companies most adept at deploying the latest science has to offer will enjoy much higher profit margins than those slow to adapt.
But the science goes far beyond the field or greenhouse.
Many marijuana investors are concerned by U.S. Attorney General Jeff Sessions' efforts to dismantle the nation's burgeoning marijuana industry. However, some of his policies have been immensely beneficial for a small sector of cannabis stocks. Today, we're looking at the three top marijuana stocks under $5 to watch that are set for huge profits under Mr. Sessions' crackdown.
Finding the top marijuana penny stocks for 2018 isn't easy.
There are almost too many choices to count when it comes to marijuana stocks.
That's why we published a list of three of the top marijuana penny stocks to watch...
A majority of Americans now favor legalizing marijuana, with 29 states already legalizing medicinal marijuana, making cannabis one of the most exciting new industries to invest in.
That's why today we'll show you our three best marijuana penny stocks to buy in 2018.
Now make no mistake: Despite Sessions' attempts to re-criminalize marijuana users and businesses, the marijuana market continues growing as legalization spreads to more states.
U.S. Attorney General Jeff Sessions is committed to giving American small marijuana business owners an edge over larger competitors.
At least, that's what it seems like to us…
You see, Mr. Sessions' anti-marijuana measures only prevent larger, billion-dollar firms from entering the U.S. marijuana industry. As a result, marijuana penny stocks trading on over-the-counter (OTC) exchanges are flourishing.
by Jack Delaney
The top marijuana stocks are skyrocketing because of increased sales in cannabis.
That's why each week, we provide Money Morning readers with marijuana industry news that could move pot stock prices.
